S&P 500   3,831.42 (+0.31%)
DOW   31,387.64 (+0.38%)
QQQ   310.46 (+0.42%)
AAPL   122.33 (+0.22%)
MSFT   231.10 (+1.56%)
FB   264.56 (+3.58%)
GOOGL   2,054.71 (+2.15%)
TSLA   643.88 (-1.43%)
AMZN   3,046.00 (+1.36%)
NVDA   507.14 (-0.99%)
BABA   233.96 (-0.98%)
CGC   31.61 (-4.90%)
GE   13.59 (+1.12%)
MU   86.78 (-2.61%)
NIO   40.54 (-2.38%)
AMD   80.17 (-0.85%)
T   28.96 (+0.84%)
F   12.13 (-0.33%)
ACB   10.00 (-4.40%)
DIS   189.82 (-1.27%)
BA   229.65 (+0.48%)
NFLX   527.15 (+1.24%)
PFE   34.80 (+1.19%)
S&P 500   3,831.42 (+0.31%)
DOW   31,387.64 (+0.38%)
QQQ   310.46 (+0.42%)
AAPL   122.33 (+0.22%)
MSFT   231.10 (+1.56%)
FB   264.56 (+3.58%)
GOOGL   2,054.71 (+2.15%)
TSLA   643.88 (-1.43%)
AMZN   3,046.00 (+1.36%)
NVDA   507.14 (-0.99%)
BABA   233.96 (-0.98%)
CGC   31.61 (-4.90%)
GE   13.59 (+1.12%)
MU   86.78 (-2.61%)
NIO   40.54 (-2.38%)
AMD   80.17 (-0.85%)
T   28.96 (+0.84%)
F   12.13 (-0.33%)
ACB   10.00 (-4.40%)
DIS   189.82 (-1.27%)
BA   229.65 (+0.48%)
NFLX   527.15 (+1.24%)
PFE   34.80 (+1.19%)
S&P 500   3,831.42 (+0.31%)
DOW   31,387.64 (+0.38%)
QQQ   310.46 (+0.42%)
AAPL   122.33 (+0.22%)
MSFT   231.10 (+1.56%)
FB   264.56 (+3.58%)
GOOGL   2,054.71 (+2.15%)
TSLA   643.88 (-1.43%)
AMZN   3,046.00 (+1.36%)
NVDA   507.14 (-0.99%)
BABA   233.96 (-0.98%)
CGC   31.61 (-4.90%)
GE   13.59 (+1.12%)
MU   86.78 (-2.61%)
NIO   40.54 (-2.38%)
AMD   80.17 (-0.85%)
T   28.96 (+0.84%)
F   12.13 (-0.33%)
ACB   10.00 (-4.40%)
DIS   189.82 (-1.27%)
BA   229.65 (+0.48%)
NFLX   527.15 (+1.24%)
PFE   34.80 (+1.19%)
S&P 500   3,831.42 (+0.31%)
DOW   31,387.64 (+0.38%)
QQQ   310.46 (+0.42%)
AAPL   122.33 (+0.22%)
MSFT   231.10 (+1.56%)
FB   264.56 (+3.58%)
GOOGL   2,054.71 (+2.15%)
TSLA   643.88 (-1.43%)
AMZN   3,046.00 (+1.36%)
NVDA   507.14 (-0.99%)
BABA   233.96 (-0.98%)
CGC   31.61 (-4.90%)
GE   13.59 (+1.12%)
MU   86.78 (-2.61%)
NIO   40.54 (-2.38%)
AMD   80.17 (-0.85%)
T   28.96 (+0.84%)
F   12.13 (-0.33%)
ACB   10.00 (-4.40%)
DIS   189.82 (-1.27%)
BA   229.65 (+0.48%)
NFLX   527.15 (+1.24%)
PFE   34.80 (+1.19%)
Log in
NASDAQ:ORMP

Oramed Pharmaceuticals News Headlines

$7.88
-0.92 (-10.45 %)
(As of 03/4/2021 11:04 AM ET)
Add
Compare
Today's Range
$7.70
Now: $7.88
$8.53
50-Day Range
$4.31
MA: $8.18
$11.33
52-Week Range
$2.40
Now: $7.88
$11.71
Volume20,151 shs
Average Volume722,371 shs
Market Capitalization$231.44 million
P/E RatioN/A
Dividend YieldN/A
Beta1.98

Headlines

Oramed Pharmaceuticals (NASDAQ ORMP) News Headlines Today

Source:
SourceHeadline
Oramed Pharmaceuticals (NASDAQ:ORMP) Stock Rating Reaffirmed by AegisOramed Pharmaceuticals (NASDAQ:ORMP) Stock Rating Reaffirmed by Aegis
marketbeat.com - February 18 at 6:53 AM
Oramed to Present at H.C. Wainwright Global Life Sciences Conference 2021Oramed to Present at H.C. Wainwright Global Life Sciences Conference 2021
finance.yahoo.com - March 4 at 9:29 AM
Oramed Pharmaceuticals (NASDAQ:ORMP) Stock Price Up 5.2%Oramed Pharmaceuticals (NASDAQ:ORMP) Stock Price Up 5.2%
americanbankingnews.com - February 24 at 10:38 PM
Oramed Pharmaceuticals (NASDAQ:ORMP)  Shares Down 11.6% Oramed Pharmaceuticals (NASDAQ:ORMP) Shares Down 11.6%
americanbankingnews.com - February 22 at 10:20 PM
Oramed Pharmaceuticals (NASDAQ:ORMP) Rating Reiterated by AegisOramed Pharmaceuticals (NASDAQ:ORMP) Rating Reiterated by Aegis
americanbankingnews.com - February 18 at 6:52 AM
Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) Short Interest Up 54.8% in JanuaryOramed Pharmaceuticals Inc. (NASDAQ:ORMP) Short Interest Up 54.8% in January
americanbankingnews.com - February 14 at 12:20 PM
Oramed Pharmaceuticals (NASDAQ:ORMP) Shares Up 7.8%Oramed Pharmaceuticals (NASDAQ:ORMP) Shares Up 7.8%
americanbankingnews.com - February 12 at 7:50 PM
Oramed Pharmaceuticals (NASDAQ:ORMP) Now Covered by National SecuritiesOramed Pharmaceuticals (NASDAQ:ORMP) Now Covered by National Securities
americanbankingnews.com - February 9 at 9:15 AM
Oramed Doses Patients Across Multiple Sites in Phase 3 Oral Insulin StudyOramed Doses Patients Across Multiple Sites in Phase 3 Oral Insulin Study
finance.yahoo.com - January 21 at 12:43 PM
Were Hopeful That Oramed Pharmaceuticals (NASDAQ:ORMP) Will Use Its Cash WiselyWe're Hopeful That Oramed Pharmaceuticals (NASDAQ:ORMP) Will Use Its Cash Wisely
finance.yahoo.com - January 8 at 2:21 PM
Oramed to Present at H.C. Wainwright BioConnect 2021 ConferenceOramed to Present at H.C. Wainwright BioConnect 2021 Conference
finance.yahoo.com - January 7 at 1:18 PM
Oramed Reports Positive First in Human Data from Oral Leptin StudyOramed Reports Positive First in Human Data from Oral Leptin Study
finance.yahoo.com - December 23 at 11:59 AM
ORMP: ORMD-0801 in Phase 3 TD2 and NASH Clinical StudiesORMP: ORMD-0801 in Phase 3 TD2 and NASH Clinical Studies
finance.yahoo.com - December 10 at 6:04 PM
Oramed launches late-stage NASH study with oral insulinOramed launches late-stage NASH study with oral insulin
seekingalpha.com - December 4 at 6:28 PM
Is Oramed Pharmaceuticals (ORMP) A Good Stock To Buy Now?Is Oramed Pharmaceuticals (ORMP) A Good Stock To Buy Now?
finance.yahoo.com - December 4 at 2:07 AM
Oramed Initiates Phase 2 NASH Trial of Oral InsulinOramed Initiates Phase 2 NASH Trial of Oral Insulin
finance.yahoo.com - December 2 at 6:01 PM
Thinking about buying stock in Hancock Jaffe, Oramed Pharmaceuticals, Tilray, Hexo Corp, or Arbutus Biopharma?Thinking about buying stock in Hancock Jaffe, Oramed Pharmaceuticals, Tilray, Hexo Corp, or Arbutus Biopharma?
marketwatch.com - December 1 at 1:16 AM
Oramed Pharma screens first patients under its Phase 3 oral insulin trial, shares +8%Oramed Pharma screens first patients under its Phase 3 oral insulin trial, shares +8%
seekingalpha.com - November 24 at 12:35 PM
Oramed Initiates Phase 3 Trial of Oral InsulinOramed Initiates Phase 3 Trial of Oral Insulin
finance.yahoo.com - November 24 at 12:35 PM
Oramed Pharmaceuticals Inc. Common Stock (ORMP)Oramed Pharmaceuticals Inc. Common Stock (ORMP)
nasdaq.com - November 19 at 7:07 PM
Nobel Laureate, Oramed SAB member Prof. Avram Hershko and Oramed CSO Dr. Miriam Kidron to be Featured on Biotalknology Webinar "Oral Delivery of Therapeutic Proteins - Oramed Story" on November 18, 2020Nobel Laureate, Oramed SAB member Prof. Avram Hershko and Oramed CSO Dr. Miriam Kidron to be Featured on Biotalknology Webinar "Oral Delivery of Therapeutic Proteins - Oramed Story" on November 18, 2020
prnewswire.com - November 12 at 8:57 AM
Oramed to Present at H.C. Wainwright 6th Annual Israel ConferenceOramed to Present at H.C. Wainwright 6th Annual Israel Conference
finance.yahoo.com - November 10 at 9:13 AM
Oramed Pharmaceuticals(NASDAQ:ORMP) Share Price Is Down 71% Over The Past Three Years.Oramed Pharmaceuticals'(NASDAQ:ORMP) Share Price Is Down 71% Over The Past Three Years.
finance.yahoo.com - November 9 at 1:36 PM
Oramed to Present Phase 2b Oral Insulin Data at American Association of Pharmaceutical Scientists 2020 PharmSci 360 ConferenceOramed to Present Phase 2b Oral Insulin Data at American Association of Pharmaceutical Scientists 2020 PharmSci 360 Conference
finance.yahoo.com - October 28 at 12:51 PM
Oramed CEO Nadav Kidron & Premas Biotech to Host Webinar "The Journey of Oral Insulin: Oramed Story" on Wednesday October 28, 2020Oramed CEO Nadav Kidron & Premas Biotech to Host Webinar "The Journey of Oral Insulin: Oramed Story" on Wednesday October 28, 2020
finance.yahoo.com - October 27 at 9:36 AM
Oramed updates on Phase 3 oral insulin studies: protocols submitted to FDAOramed updates on Phase 3 oral insulin studies: protocols submitted to FDA
seekingalpha.com - October 16 at 12:49 PM
Oramed Issues Shareholder Update on Pivotal Phase 3 Oral Insulin Studies: Protocols Submitted to FDAOramed Issues Shareholder Update on Pivotal Phase 3 Oral Insulin Studies: Protocols Submitted to FDA
finance.yahoo.com - October 16 at 12:49 PM
ORMP: Advancing Toward Phase 3 Program For ORMD-0801ORMP: Advancing Toward Phase 3 Program For ORMD-0801
finance.yahoo.com - September 22 at 1:34 PM
Oramed Pharmaceuticals to Present at the European Association for the Study of Diabetes (EASD) Annual MeetingOramed Pharmaceuticals to Present at the European Association for the Study of Diabetes (EASD) Annual Meeting
finance.yahoo.com - September 21 at 12:27 PM
Orameds Diabetes Market Survey Shows Strong Support for ORMD-0801 Oral Insulin Among Physicians and PatientsOramed's Diabetes Market Survey Shows Strong Support for ORMD-0801 Oral Insulin Among Physicians and Patients
prnewswire.com - September 15 at 12:45 PM
Oramed's Diabetes Market Survey Shows Strong Support for ORMD-0801 Oral Insulin Among Physicians and PatientsOramed's Diabetes Market Survey Shows Strong Support for ORMD-0801 Oral Insulin Among Physicians and Patients
finance.yahoo.com - September 15 at 12:45 PM
How Much Is Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) CEO Getting Paid?How Much Is Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) CEO Getting Paid?
finance.yahoo.com - August 11 at 4:04 PM
Oramed announces successful end of Phase 2 meeting with FDA for oral insulinOramed announces successful end of Phase 2 meeting with FDA for oral insulin
seekingalpha.com - July 15 at 1:49 PM
Oramed on go with late-stage oral insulin studiesOramed on go with late-stage oral insulin studies
seekingalpha.com - July 15 at 1:49 PM
Oramed Reports Positive End of Phase 2 Meeting With the FDA for Oral InsulinOramed Reports Positive End of Phase 2 Meeting With the FDA for Oral Insulin
finance.yahoo.com - July 15 at 1:49 PM
Insulin in Pill Form Would Be a Bonanza for OramedInsulin in Pill Form Would Be a Bonanza for Oramed
finance.yahoo.com - July 8 at 8:10 PM
Oramed Pharmaceuticals EPS beats by $0.10, beats on revenueOramed Pharmaceuticals EPS beats by $0.10, beats on revenue
seekingalpha.com - July 8 at 3:10 PM
ORMP: Positive Takeaways of Preliminary NASH Study FindingsORMP: Positive Takeaways of Preliminary NASH Study Findings
finance.yahoo.com - June 19 at 1:28 PM
Oramed Announces Positive Initial Clinical Trial Results for Treatment of NASH With Oral InsulinOramed Announces Positive Initial Clinical Trial Results for Treatment of NASH With Oral Insulin
finance.yahoo.com - June 15 at 9:52 AM
ORMP Oramed Pharmaceuticals Inc. Common StockORMP Oramed Pharmaceuticals Inc. Common Stock
www.nasdaq.com - June 14 at 12:25 AM
The Daily Biotech Pulse: FDA Nod For Viela, 3 IPOs And Hematology Congress PresentationsThe Daily Biotech Pulse: FDA Nod For Viela, 3 IPOs And Hematology Congress Presentations
www.benzinga.com - June 12 at 8:38 AM
Newsflash: Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) Analysts Have Been Trimming Their Revenue ForecastsNewsflash: Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) Analysts Have Been Trimming Their Revenue Forecasts
finance.yahoo.com - June 9 at 12:00 PM
Oramed Pharmaceuticals Inc. (ORMP): Are Hedge Funds Right About This Stock?Oramed Pharmaceuticals Inc. (ORMP): Are Hedge Funds Right About This Stock?
finance.yahoo.com - June 4 at 8:26 PM
Will Oramed Pharmaceuticals (NASDAQ:ORMP) Spend Its Cash Wisely?Will Oramed Pharmaceuticals (NASDAQ:ORMP) Spend Its Cash Wisely?
finance.yahoo.com - May 5 at 5:44 PM
Oramed Pharmaceuticals to Present at the 80th American Diabetes Association Scientific Session, to be Held Virtually This Year in JuneOramed Pharmaceuticals to Present at the 80th American Diabetes Association Scientific Session, to be Held Virtually This Year in June
finance.yahoo.com - May 5 at 8:45 AM
ORMP: Second quarter financial results; Strengthens Advisory Board; Positive EoP2 meeting with the FDAORMP: Second quarter financial results; Strengthens Advisory Board; Positive EoP2 meeting with the FDA
finance.yahoo.com - April 14 at 1:18 PM
Oramed Patent in Canada Allowed for Oral Delivery of ProteinsOramed Patent in Canada Allowed for Oral Delivery of Proteins
finance.yahoo.com - April 7 at 7:45 AM
Oramed Pharmaceuticals Issues CEO Shareholder Letter Providing Business Update Amid COVID-19Oramed Pharmaceuticals Issues CEO Shareholder Letter Providing Business Update Amid COVID-19
finance.yahoo.com - April 1 at 3:57 PM
Does Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) Have A Particularly Volatile Share Price?Does Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) Have A Particularly Volatile Share Price?
finance.yahoo.com - March 30 at 8:14 PM
Oramed up 7% premarket on advancement of oral insulinOramed up 7% premarket on advancement of oral insulin
seekingalpha.com - March 19 at 12:46 PM
Oramed Receives Positive Feedback From End-of-Phase 2 Oral Insulin CMC Meeting With FDAOramed Receives Positive Feedback From End-of-Phase 2 Oral Insulin CMC Meeting With FDA
finance.yahoo.com - March 19 at 12:46 PM
This page was last updated on 3/4/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.